search
Dr. Tal Zaks
An entrance to a Moderna, Inc., building, May 18, 2020, in Cambridge, Massachusetts. (AP Photo/Bill Sikes)
May 28, 2020, 3:21 am
Amid virus vaccine hopes, Moderna top execs said to have sold millions in stocks
US biotech firm’s shares soared when it claimed progress in trials; analysts say sales, including by Israeli chief medical officer, are legal but undermine faith in company
By TOI staff and Agencies
In this March 16, 2020, file photo, a pharmacist gives Jennifer Haller, left, the first shot in the first-stage safety study clinical trial of a potential vaccine for COVID-19, the disease caused by the new coronavirus, at the Kaiser Permanente Washington Health Research Institute in Seattle. The vaccine by Cambridge, Massachusetts-based Moderna Inc., generated antibodies similar to those seen in people who have recovered from COVID-19 in a study volunteers who were given either a low or medium dose. (AP Photo/Ted S. Warren, File)
May 18, 2020, 9:04 pm
Moderna’s Israeli top medical officer: We’ve shown today that our vaccine works
US biotech firm’s shares soar as it claims tests of first volunteers show its vaccine candidate produces immune response, ‘has potential to prevent COVID-19’; Phase 3 tests in July
By TOI staff and Agencies
Load More
Is our work important
to you?

Does The Times of Israel give you valuable insight into Israel and the Jewish world?
If so, please join The Times of Israel Community.
For as little as $6/month, you will:

  • Support our independent journalism;
  • Enjoy an ad-free experience on the ToI site, apps and emails; and
  • Unlock exclusive content shared only with the ToI Community, like our new Behind the Headlines interview series with thought leaders, and weekly letters from founding editor David Horovitz.
Join the times of israel community Join our community Already a member? Sign in to stop seeing this